Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Study for a 2-year Period to Confirm the Safety and Immunogenicity of the Candidate Malaria Vaccine RTS,S/AS02A in Mozambican Children Aged 1 to 4 Years at the Time of First Vaccine Dose.

NCT00323622 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00323622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00323622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Study for a 2-year Period to Confirm the Safety and Immunogenicity of the Candidate Malaria Vaccine RTS,S/AS02A in Mozambican Children Aged 1 to 4 Years at the Time of First Vaccine Dose.
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2005
Completion date
May 31, 2007
Enrollment
1,737 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria